Product
Branaplam
Aliases
LMI070
1 clinical trial
1 indication
Indication
Huntington's diseaseClinical trial
A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study With Open-Label Extension to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of LMI070/Branaplam Administered as Weekly Oral Doses in Participants With Early Manifest Huntington's DiseaseStatus: Completed, Estimated PCD: 2023-10-27